


INNATE IMMUNITY

PRR LIGANDS



The most comprehensive library of PAMPs

- Largest collection of PRR agonists and antagonists
- Highest quality ligands
- Activity and contaminant levels thoroughly tested

Pattern recognition receptors (PRRs) recognize a wide variety of ligands, called pathogen-associated molecular patterns (PAMPs), discriminating bacteria, fungi and other pathogens. InvivoGen offers the most comprehensive choice of ligands known to activate specific PRRs. InvivoGen strives to provide PRR ligands of the highest quality by thoroughly validating our ligands to ensure lot-to-lot reproducibility.

Choose from our extensive collection:

- TLR Ligands
- NLR Ligands
- RLR Ligands
- CLR Ligands
- CDS/STING Ligands
- Inflammasome Inducers
- Microbiota Ligands
- Multi-PRR Ligands

WWW.INVIVOCOM/LIGANDS

PRR LIGANDS

The innate immune system is an evolutionarily conserved system acting as a first-line of defense against invading microbial pathogens and other potential threats to the host. A range of pattern recognition receptors (PRRs) recognize specific pathogen-associated molecular patterns (PAMPs) exclusively present on microbes such as bacteria, fungi, parasites, and viruses. The main PRR families of the innate immune system are the Toll-Like receptors (TLRs), NOD-Like receptors (NLRs), C-type lectin receptors (CLRs), RIG-I-Like receptors (RLRs), cytosolic DNA sensors (CDS), and the aryl hydrocarbon receptor (AhR). InvivoGen offers a comprehensive range of high quality PAMPs known to activate these PRRs.

TLR Ligands

TLR2 Agonists

TLR2 (also known as CD282) is a membrane surface receptor involved in the recognition of a wide array of microbial molecules. These molecules represent broad groups of species, such as Gram-positive and Gram-negative bacteria, as well as mycoplasma and yeast. They include peptidoglycan, lipoteichoic acid, and lipoproteins from bacteria, lipoarabinomannan from mycobacteria, and zymosan from yeast cell walls. The variety of TLR2 ligands is the greatest among all the TLRs and this is due to the heterodimerization needed for TLR2-mediated responses. TLR2 forms a heterodimer with TLR6 to recognize diacylated lipoproteins, whereas the TLR1/TLR2 heterodimer binds triacylated lipoproteins. Moreover, the CD14 co-receptor enhances pathogen recognition by TLR2. TLR2 signaling is MyD88 (myeloid differentiation primary-response protein 88)-dependent and requires the adaptor molecule TIRAP (TIR-associated protein) to induce the production of pro-inflammatory cytokines following AP-1 (activator protein 1) and NF- κ B (nuclear factor- κ B) nuclear translocation.

TLR3 Agonists

TLR3 (also known as CD283) is an endosomal receptor that recognizes double-stranded RNA (dsRNA), a molecular pattern associated with viral infection. Polyinosine-polycytidylic acid (poly(I:C)), a synthetic analog of dsRNA, is the ligand of choice for TLR3. TLR3 signals mainly through a MyD88-independent pathway involving the adapter protein TRIF (TIR domain-containing adaptor protein-inducing IFN- β). Phosphorylation of IRF3 (IFN regulatory factor 3) leads to the production of IFN- β (interferon β) with the subsequent activation of IFN-stimulated response elements (ISRE). Additionally, TLR3 signaling leads to the nuclear translocation of AP-1 and NF- κ B and to the production of pro-inflammatory cytokines.

TLR4 Agonists

TLR4 is the receptor for Gram-negative lipopolysaccharide (LPS) and lipid A, its toxic moiety. In order to respond to LPS, TLR4 interacts with three different extracellular proteins: LPS binding protein (LBP), CD14 and myeloid differentiation protein 2 (MD-2). TLR4 signaling comprises two pathways: the MyD88-dependent and MyD88-independent pathways. The MyD88-dependent pathway involves AP-1 and NF- κ B nuclear translocation and leads to the production of inflammatory cytokines. The MyD88-independent pathway activates IRF3 and involves another adaptor molecule, TRAM (TRIF-related adaptor molecule), and leads to the production of IFN- β and the expression of IFN-inducible genes through the activation of IRF3.

TLR5 Agonists

The cell surface receptor TLR5 recognizes flagellin, the major component of the bacterial flagellar filament, from both Gram-positive and Gram-negative bacteria. Activation of TLR5 stimulates the production of pro-inflammatory

cytokines through signaling via the adaptor protein MyD88. As a homodimer, TLR5 can generate a pro-inflammatory signal, suggesting that it might be the only TLR participating in flagellin recognition.

TLR7/8 Agonists

TLR7 and TLR8 are endosomal receptors involved in the response to viral infection. They recognize GU-rich short single-stranded RNA, as well as small synthetic molecules, such as imidazoquinolines and nucleoside analogues. TLR7/TLR8 signaling is MyD88-dependent and is mediated by the nuclear translocation of AP-1 and NF- κ B, in addition to the phosphorylation of IRF7 (IFN regulatory factor 7). IRF7 promotes the induction of ISRE and the subsequent expression of type I IFN genes, whereas AP-1 and NF- κ B activation results in the production of pro-inflammatory cytokines.

TLR9 Agonists

The endosomal receptor TLR9 (also known as CD289) recognizes specific unmethylated CpG-ODN sequences that distinguish microbial DNA from mammalian DNA. Three types of stimulatory ODNs have been described: Class A (Type D), Class B (Type K) and Class C. Similar to most other TLRs, TLR9 signaling is MyD88-dependent, involving the transcription factors AP-1, NF- κ B, and IRF7. TLR9-induced pro-inflammatory cytokine production is mediated by AP-1 and NF- κ B, whereas TLR9-induced IFN- α/β production is mediated by IRF7. The cytokine and IFN response is highly dependent on the class of CpG-ODN used to stimulate TLR9.


TLR13 Agonists

TLR13 is an endosomal TLR expressed in mice. Although its role and ligands remain unclear, 23S ribosomal RNA (rRNA) has been identified as a TLR13 ligand. TLR13 induces cytokine production in a MyD88- and UNC93B-dependent manner through the activation of AP-1 and NF- κ B. TLR13 signaling also results in IFN- β production through the activation of IRF7. Humans lack TLR13 and probably rely on other pathogen receptors to detect pathogenic bacterial infection.

NLR Ligands

NOD1/2 Agonists

NOD1 (also known as CARD4) and NOD2 (also known as CARD15) are intracellular PRRs that sense bacterial peptidoglycans (PGNs). NOD1 senses the D- γ -glutamyl-meso-DAP dipeptide (iE-DAP), which is found in PGNs of all Gram-negative and certain Gram-positive bacteria, whereas NOD2 recognizes the muramyl dipeptide (MDP) structure found in almost all bacteria. Both iE-DAP and MDP must be delivered intracellularly either by bacteria that invade the cell or through other cellular uptake mechanisms. Ligand-bound NOD1 and NOD2 oligomerize and signal via the serine/threonine RIP2 kinase. Once activated, RIP2 mediates ubiquitination of NEMO/IKK γ leading to the activation of NF- κ B and the production of inflammatory cytokines.



Inflammasome Inducers

Inflammasomes are multimeric protein complexes that are generally comprised of a member of the NLR family, such as NLRP3 and NLRC4, the adaptor protein ASC (apoptosis-associated speck-like protein with a CARD) and pro-caspase-1. They assemble in the cytoplasm of innate immune cells in response to cytosolic PAMPs or DAMPs (danger-associated molecular patterns). They promote the secretion of the pro-inflammatory cytokines IL-1 β and IL-18 and cause a rapid and pro-inflammatory form of cell death called pyroptosis. The most intensely studied inflammasome is the NLRP3 (NLR family, pyrin domain containing 3) inflammasome. It is activated by a broad variety of stimuli, including danger signals (e.g. ATP), crystalline substances (e.g. MSU) and microbial toxins (e.g. nigericin). The NLRC4 (NLR containing a caspase activating and recruitment domain 4) /NAIP (neuronal apoptosis inhibitory protein) inflammasome is triggered by cytosolic flagellin from various bacteria, such as *Salmonella typhimurium* and *Pseudomonas aeruginosa*. The NLRP1 inflammasome induces caspase-1 in response to diverse stimuli, including *Bacillus anthracis* lethal toxin, *Toxoplasma gondii*, muramyl dipeptide, and host intracellular ATP depletion.

RLR Ligands

RIG-I/MDA-5 Agonists

RIG-I and MDA-5 are cytoplasmic RNA helicases that recognize intracellular double-stranded RNA (dsRNA), a molecular pattern associated with viral infection. Despite their overall structural similarity, they detect distinct viral species. RIG-I participates in the recognition of Paramyxoviruses (Newcastle disease virus (NDV), Sendai virus (SeV)), Rhabdoviruses (vesicular stomatitis virus (VSV)), Flaviviruses (hepatitis C (HCV)) and Orthomyxoviruses (Influenza), whereas MDA-5 is essential for the recognition of Picornaviruses (encephalo-myocarditis virus (EMCV)) and poly(I:C), a synthetic analog of viral dsRNA. Although RIG-I and MDA-5 recognize different ligands, they share common signaling features. Upon recognition of dsRNA, they are recruited by the adaptor IPS-1 (also known as MAVS, CARDIF or VISA) to the outer membrane of the mitochondria, leading to the activation of several transcription factors including IRF3, IRF7 and NF- κ B. IRF3 and IRF7 control expression of type I IFNs, while NF- κ B regulates the production of pro-inflammatory cytokines.

CLR Ligands

Dectin-1 Agonists

Dectin-1 is a member of the C-type lectin receptor (CLR) family and plays an important role in antifungal innate immunity. Dectin-1 is a specific transmembrane receptor of b-glucans, which are glucose polymers found

in the cell walls of fungi, including the yeasts *Saccharomyces cerevisiae* and *Candida albicans*. Upon binding to its ligand, Dectin-1 triggers phagocytosis and signaling through the kinase Syk and the adaptors CARD9-Bcl10-Malt1, leading to the production of reactive oxygen species (ROS), the activation of NF- κ B and the subsequent production of pro-inflammatory cytokines. Dectin-1 and TLR2 work in tandem to enhance their respective signaling responses.

Dectin-2 Agonists

Dectin-2 is a type II transmembrane CLR that binds high mannose-type carbohydrates and was shown to be the functional receptor for α -mannans. Upon binding to its ligand, Dectin-2 signals through the kinase Syk and the adaptors CARD9/Bcl-10/MALT1 triggering the activation of NF- κ B and the subsequent production of pro-inflammatory cytokines. Dectin-2 is implicated in anti-bacterial immunity and allergy.

Mincle Agonists

Mincle is a multi-functional danger receptor that recognizes a wide variety of ligands such as damaged cells, fungus, yeast and mycobacteria. Exogenous ligands for Mincle include fungal α -mannose, and the mycobacterial glycolipid, trehalose-6'6'-dimycolate (TDM; also known as cord factor) the immunostimulatory component of *Mycobacterium tuberculosis*. Furthermore, Mincle senses damaged cells by recognizing endogenous DAMPs. One such DAMP identified is the spliceosome-associated protein 130 (SAP130), a soluble factor released by necrotic cells. Mincle triggers signaling through Syk leading to CARD9-dependent NF- κ B activation. Syk induces also the mobilization of intracellular calcium (Ca^{2+}) and the activation of the calcineurin-NFAT pathway.

CDS & STING Ligands

Cytosolic DNA Sensor (CDS) Agonists

CDSs detect damaged, mislocalized or pathogenic DNA, typically inducing type I IFN production through the TBK1-IRF3 pathway. DNA is normally compartmentalized in the nucleus or mitochondria; however, if it is not processed or transported correctly, then it can accumulate in the cytosol. Alternatively, viral or microbial DNA can enter the cytosol of host cells upon infection. Several CDSs have been identified, including the adenosine deaminase DAI, the helicase DDX41, the IFN-inducible IFI16 protein, and cGAS (cyclic GMP-AMP synthase). AIM2 is another cytosolic DNA sensor, which upon activation forms an inflammasome that leads to the secretion of IL-1 β .

STING Agonists

STING, initially thought to serve solely as an adaptor protein for mediating signaling by CDSs, was found to be a direct sensor of cyclic dinucleotides (CDNs). CDNs are important messengers in bacteria, affecting numerous responses of the prokaryotic cell, as well as in mammalian cells, acting as drivers of the innate immune response. CDNs and xanthenone derivatives, such as DMXAA, bind to and activate STING, leading to a potent type I IFN response in a TBK1-IRF3-dependent manner.

AhR Ligands

AhR Agonists

The aryl hydrocarbon receptor (AhR) is a ligand-dependent transcriptional factor capable of sensing a wide range of structurally different exogenous and endogenous molecules. AhR ligands vary in their structure, and their binding affinity can significantly differ between mouse and human AhR. AhR agonists have been found to arise from xenobiotics such as pollutants, and indoles mainly derived from tryptophan metabolism occurring in the stomach and in the gut, as well as in other organs upon photo-oxidation or oxidative stress.

PRR Ligands

*To ensure the **absence** of bacterial contaminants (i.e. lipoproteins and endotoxins), TLR2 and TLR4 activation has been assessed by cellular assays.

| PRODUCT | ORIGIN/DESCRIPTION | GRADE* | WORKING CONCENTRATION | QTY | CATALOG CODE |
|-----------------------------|--|----------------|--|------------------------|----------------------------|
| TLR LIGANDS | | | | | |
| TLR2 Agonists | | | | | |
| CU-T12-9 NEW | Synthetic TLR2-TLR1 compound | TLR2 +/ TLR4 - | 10nM – 10µM | 10mg | tlrl-cut129 |
| CL401 VacciGrade™ | Preclinical grade CL401 | VacciGrade™ | 20 - 50 µg/mouse | 5 mg | vac-c401-5 |
| CL413 - Adilipoline™ | PAM2CK4-conjugated hydroxyadenine compound | TLR2 +/ TLR4 - | 50 pg - 10 µg/ml | 500 µg | tlrl-c413 |
| CL413 VacciGrade™ | Preclinical grade CL413 | VacciGrade™ | 20 - 50 µg/mouse | 5 mg | vac-c413-5 |
| CL429 | Pam2C-conjugated murabutide | TLR2 +/ TLR4 - | 1 ng - 10 µg/ml | 5 mg | tlrl-c429 |
| CL429 VacciGrade™ | Preclinical grade CL429 | VacciGrade™ | 20 - 50 µg/mouse | 5 mg | vac-c429 |
| CU-T12-9 | Synthetic TLR2-TLR1 compound | TLR2 +/ TLR4 - | 10nM – 10µM | 10mg | tlrl-cut129 |
| FSL-1 | Synthetic diacylated lipoprotein - TLR2/6 | TLR2 +/ TLR4 - | 1 - 100 ng/ml | 100 µg | tlrl-fsl |
| HKBF | Heat Killed <i>Bacteroides fragilis</i> | TLR2 +/ TLR4 - | 10 ⁶ - 10 ⁷ cells/m | 10 ⁹ cells | tlrl-hkbf |
| HKEB | Heat Killed <i>Escherichia coli</i> O111:B4 | TLR2 +/ TLR4 + | 10 ⁵ - 10 ⁷ cells/ml | 10 ¹⁰ cells | tlrl-hkeb |
| HKLM | Heat Killed <i>Listeria monocytogenes</i> | TLR2 +/ TLR4 - | 10 ⁷ - 10 ⁸ cells/ml | 10 ¹⁰ cells | tlrl-hklm |
| HKLR | Heat Killed <i>Lactobacillus rhamnosus</i> | TLR2 +/ TLR4 - | 10 ⁸ - 10 ⁹ cells/ml | 10 ¹⁰ cells | tlrl-hklr |
| HKMT | Heat Killed <i>Mycobacterium tuberculosis</i> | TLR2 +/ TLR4 - | 100 ng - 10 µg/ml | 10 mg 50 mg | tlrl-hkmt-1 tlrl-hkmt-5 |
| HKPA | Heat Killed <i>Pseudomonas aeruginosa</i> | TLR2 +/ TLR4 - | 10 ⁵ - 10 ⁷ cells/ml | 10 ¹⁰ cells | tlrl-hkpa |
| HKSA | Heat Killed <i>Staphylococcus aureus</i> | TLR2 +/ TLR4 - | 10 ⁶ - 10 ⁸ cells/ml | 10 ¹⁰ cells | tlrl-hksa |
| HKSE | Heat Killed <i>Staphylococcus epidermidis</i> | TLR2 +/ TLR4 - | 10 ⁷ - 10 ⁹ cells/ml | 10 ¹⁰ cells | tlrl-hkse |
| HKSP | Heat Killed <i>Streptococcus pneumoniae</i> | TLR2 +/ TLR4 - | 10 ⁷ - 10 ⁹ cells/ml | 10 ¹⁰ cells | tlrl-hksp |
| HKST | Heat Killed <i>Salmonella typhimurium</i> | TLR2 +/ TLR4 + | 10 ⁴ - 10 ⁹ cells/ml | 10 ¹⁰ cells | tlrl-hkst |
| LPS-PG | Standard Lipopolysaccharide from <i>P. gingivalis</i> | TLR2 +/ TLR4 + | 10 ng - 10 mg/ml | 1 mg | tlrl-pglps |
| LTA-BS | Lipoteichoic acid from <i>Bacillus subtilis</i> | TLR2 +/ TLR4 + | 100 ng - 1 µg/ml | 5 mg | tlrl-lta |
| LTA-SA | Lipoteichoic acid from <i>S. aureus</i> | TLR2 +/ TLR4 + | 100 ng - 1 µg/ml | 5 mg | tlrl-shta |
| LTA-SA Purified | Purified lipoteichoic acid from <i>S. aureus</i> | TLR2 +/ TLR4 - | 1 ng - 1 µg/ml | 5 mg | tlrl-pslta |
| Pam2CSK4 | Synthetic diacylated lipoprotein - TLR2(6) | TLR2 +/ TLR4 - | 1 - 100 ng/ml | 1 mg | tlrl-pm2s-1 |
| Pam3CSK4 | Synthetic triacylated lipoprotein - TLR1/2 | TLR2 +/ TLR4 - | 1 - 300 ng/ml | 1 mg | tlrl-pms |
| Pam3CSK4 Biotin | Biotinylated Pam3CSK4 | TLR2 +/ TLR4 - | 10 - 300 ng/ml | 50 µg | tlrl-bpms |
| Pam3CSK4 Rhodamine | Rhodamine-labeled Pam3CSK4 | TLR2 +/ TLR4 - | 1 - 300 ng/ml | 50 µg | tlrl-rpms |
| Pam3CSK4 VacciGrade™ | Preclinical grade Pam3CSK4 | VacciGrade™ | 2 - 20 µg/mouse | 1 mg | vac-pms |
| PGN-BS | Peptidoglycan from <i>B. subtilis</i> | TLR2 +/ TLR4 - | 1 - 10 µg/ml | 5 mg | tlrl-pgnb3 |
| PGN-EK | Peptidoglycan from <i>E. coli</i> K12 | TLR2 +/ TLR4 + | 1 - 10 µg/ml | 1 mg | tlrl-pgnek |
| PGN-SA | Peptidoglycan from <i>S. aureus</i> | TLR2 +/ TLR4 - | 0.1 - 10 µg/ml | 5 mg | tlrl-pgns2 |
| Zymosan | Cell wall preparation of <i>S. cerevisiae</i> | TLR2 +/ TLR4 - | 1-10 µg/ml | 100 mg | tlrl-zyn |
| TLR3 Agonists | | | | | |
| Poly(A:U) | Polyadenylic-polyuridylic acid | TLR2 -/ TLR4 - | 300 ng- 100 µg/ml | 10 mg | tlrl-pau |
| Poly(I:C) (HMW) | Polyinosine-polycytidylic acid High molecular weight (1.5-8 kb) | TLR2 -/ TLR4 - | 30 ng - 10 µg/ml | 10 mg 50 mg | tlrl-pic tlrl-pic-5 |
| Poly(I:C) (HMW) Biotin | Biotinylated poly(I:C) (HMW) | TLR2 -/ TLR4 - | 30 ng - 10 µg/ml | 10 µg | tlrl-picb |
| Poly(I:C) (HMW) Fluorescein | Fluorescein-labeled poly(I:C) (HMW) | TLR2 -/ TLR4 - | 10 ng - 10 µg/ml | 10 µg | tlrl-picf |
| Poly(I:C) (HMW) Rhodamine | Rhodamine-labeled poly(I:C) (HMW) | TLR2 -/ TLR4 - | 10 ng - 10 µg/ml | 10 µg | tlrl-picr |
| Poly(I:C) (HMW) VacciGrade™ | Preclinical grade poly(I:C) (HMW) | VacciGrade™ | 10 µg - 100 µg/mouse | 10 mg | vac-pic |
| Poly(I:C) (LMW) | Polyinosine-polycytidylic acid Low molecular weight (0.2-1 kb) | TLR2 -/ TLR4 - | 30 ng - 10 µg/ml | 25 mg 250 mg | tlrl-picw tlrl-picw-250 |
| Poly(I:C) (LMW) Rhodamine | Rhodamine-labeled poly(I:C) (LMW) | TLR2 -/ TLR4 - | 100 ng - 10 µg/ml | 10 µg | tlrl-piwr |

PRR Ligands

* VacciGrade™ PRR ligands are guaranteed sterile and have minimal endotoxin levels (<0.005 EU/µg).

| PRODUCT | ORIGIN/DESCRIPTION | GRADE* | WORKING CONCENTRATION | QTY | CATALOG CODE |
|----------------------------|---|----------------|-----------------------|----------------------|--------------------------------|
| TLR4 Agonists | | | | | |
| CRX-527 | Synthetic Lipid A analog | TLR2 - /TLR4 + | 100 pg/ml - 10 ng/ml | 1 mg | tlrl-crx527 |
| LPS-B5 | Standard lipopolysaccharide from <i>E. coli</i> 055:B5 | TLR2 + /TLR4 + | 100 pg - 1 µg/ml | 5 mg | tlrl-b5lps |
| LPS-B5 Ultrapure | Ultrapure lipopolysaccharide from <i>E. coli</i> 055:B5 | TLR2 - /TLR4 + | 100 pg - 1 µg/ml | 5 mg | tlrl-b5lps |
| LPS-EB | Standard lipopolysaccharide from <i>E. coli</i> O111:B4 | TLR2 + /TLR4 + | 10 ng - 10 µg/ml | 5 mg | tlrl-eblps |
| LPS-EB Biotin | Biotinylated ultrapure LPS from <i>E. coli</i> O111:B4 | TLR2 + /TLR4 + | 10 ng - 10 µg/ml | 500 µg | tlrl-3blps |
| LPS-EB Ultrapure | Ultrapure lipopolysaccharide from <i>E. coli</i> O111:B4 | TLR2 - /TLR4 + | 10 ng - 10 µg/ml | 5x10 ⁶ EU | tlrl-3pelps |
| LPS-EB VacciGrade™ | Preclinical grade ultrapure LPS from <i>E. coli</i> O111:B4 | VacciGrade™ | 0.1 - 25 µg/mouse | 5x10 ⁶ EU | vac-3pelps |
| LPS-EK | Standard lipopolysaccharide from <i>E. coli</i> K12 | TLR2 + /TLR4 + | 1 ng - 10 µg/ml | 5 mg | tlrl-eklps |
| LPS-EK Ultrapure | Ultrapure lipopolysaccharide from <i>E. coli</i> K12 | TLR2 - /TLR4 + | 1 ng - 10 µg/ml | 1 mg | tlrl-peklps |
| LPS-PG | Standard lipopolysaccharide from <i>P. gingivalis</i> | TLR2 + /TLR4 + | 100 ng - 10 µg/ml | 1 mg | tlrl-pglps |
| LPS-PG Ultrapure | Ultrapure lipopolysaccharide from <i>P. gingivalis</i> | TLR2 - /TLR4 + | 100 ng - 10 µg/ml | 1 mg | tlrl-pgglps |
| LPS-SM Ultrapure | Ultrapure lipopolysaccharide from <i>S. minnesota</i> | TLR2 - /TLR4 + | 10 ng - 10 µg/ml | 5 mg | tlrl-smlps |
| MPLA-SM | Monophosphoryl lipid A from <i>S. minnesota</i> | TLR2 - /TLR4 + | 10 ng - 1 µg/ml | 1 mg | tlrl-mpla |
| MPLA-SM VacciGrade™ | Preclinical grade detoxified MPLA | VacciGrade™ | 2 - 20 µg/mouse | 1 mg | vac-mpla |
| MPLA Synthetic | Synthetic monophosphoryl lipid A | TLR2 - /TLR4 + | 300 pg - 100 ng/ml | 1 mg | tlrl-mpls |
| MPLA Synthetic VacciGrade™ | Preclinical grade synthetic MPLA | VacciGrade™ | 2 - 20 µg/mouse | 1 mg | vac-mpls |
| TLR4 Antagonist | | | | | |
| LPS-RS | Lipopolysaccharide from <i>Rhodobacter sphaeroides</i> | TLR2 + /TLR4 - | 10 ng - 10 µg/ml | 5 mg | tlrl-rslps |
| LPS-RS Ultrapure | Ultrapure lipopolysaccharide from <i>R. sphaeroides</i> | TLR2 - /TLR4 - | 10 ng - 10 µg/ml | 1 mg | tlrl-prsllps |
| TLR5 Agonists | | | | | |
| FLA-BS | Standard flagellin from <i>B. subtilis</i> - 10% pure | TLR2 + /TLR4 + | 10 ng - 10 µg/ml | 100 µg | tlrl-bsfla |
| FLA-BS Ultrapure | Ultrapure flagellin from <i>B. subtilis</i> - >95% pure | TLR2 - /TLR4 - | 1 ng - 1 µg/ml | 50 µg | tlrl-bsfla |
| FLA-PA Ultrapure | Ultrapure flagellin from <i>P. aeruginosa</i> - >95% pure | TLR2 - /TLR4 - | 1 ng - 1 µg/ml | 50 µg | tlrl-pafla |
| FLA-ST | Standard flagellin from <i>S. typhimurium</i> - 10% pure | TLR2 + /TLR4 + | 10 ng - 10 µg/ml | 100 µg | tlrl-stfla |
| FLA-ST Ultrapure | Ultrapure flagellin from <i>S. typhimurium</i> - >95% pure | TLR2 - /TLR4 - | 10 - 100 ng/ml | 10 µg 50 µg | tlrl-epstfla tlrl-epstfla-5 |
| RecFLA-ST | Recombinant flagellin from <i>S. typhimurium</i> | TLR2 - /TLR4 - | 10 - 100 ng/ml | 50 µg 10 µg | tlrl-flic-50 tlrl-flic-10 |
| Flagellin Flic VacciGrade™ | Preclinical grade RecFLA-ST | VacciGrade™ | 1 - 10 µg/mouse | 50 µg | vac-fla |
| TLR5 Antagonist | | | | | |
| hTLR5-Fc | Soluble ectodomain of TLR5 | TLR2 - /TLR4 - | 10 ng - 1 µg/ml | 50 µg | fc-htlr5 |
| TLR7 Agonists | | | | | |
| CL264 | Adenine analog | TLR2 - /TLR4 - | 50 ng - 10 µg/ml | 500 µg 5 mg | tlrl-c264e tlrl-c264e-5 |
| CL307 | Hydroxyadenine spermine compound | TLR2 - /TLR4 - | 5 ng - 1 µg/ml | 500 µg | tlrl-c307 |
| CL347 - AdiFectin™ | Hydroxyadenine spermine compound | TLR2 - /TLR4 - | 300 ng - 3 µg/ml | 500 µg | tlrl-c347 |
| CL401 VacciGrade™ | Preclinical grade CL401 | VacciGrade™ | 20 - 50 µg/mouse | 1 mg | vac-c401-5 |
| CL413 - Adilipoline™ | PAM2CK4-conjugated hydroxyadenine compound | TLR2 + /TLR4 - | 50 pg - 10 µg/ml | 500 µg | tlrl-c413 |
| CL413 VacciGrade™ | Preclinical grade CL413 | VacciGrade™ | 20 - 50 µg/mouse | 5 mg | vac-c413-5 |
| Gardiquimod™ | Imidazoquinoline compound | TLR2 - /TLR4 - | 0.1 - 3 µg/ml | 500 µg 5 mg | tlrl-gdq5 tlrl-gdq-5 |
| Imiquimod (R837) | Imidazoquinoline compound | TLR2 - /TLR4 - | 1 - 5 µg/ml | 500 µg 5 mg | tlrl-imqs tlrl-imq |
| Imiquimod VacciGrade™ | Preclinical grade Imiquimod | TLR2 - /TLR4 - | 10 - 100 µg/mouse | 5 mg | vac-imq |
| Loxoribine | Guanosine analog | TLR2 - /TLR4 - | 1 mM (300 µg/ml) | 50 mg | tlrl-lox |

PRR Ligands


*To ensure the **absence** of bacterial contaminants (i.e. lipoproteins and endotoxins), TLR2 and TLR4 activation has been assessed by cellular assays.

| PRODUCT | ORIGIN/DESCRIPTION | GRADE* | WORKING CONCENTRATION | QTY | CATALOG CODE |
|-----------------------------|---|-----------------|-----------------------|------------------------|--|
| TLR8 Agonists | | | | | |
| ORN06/LyoVec™ | ssRNA with 6 UUGU repeats / LyoVec™ | TLR2 - / TLR4 - | 0.25 - 5 µg/ml | 4x25µg | tlrl-orn6 |
| ssPolyU Naked | RNA homopolymer | TLR2 - / TLR4 - | 1 - 10 µg/ml | 10mg 10 x 10mg | tlrl-sspu tlrl-sspu-100 |
| ssPolyU/LyoVec™ | RNA homopolymer / LyoVec™ | TLR2 - / TLR4 - | 1 - 10 µg/ml | 4x25µg | tlrl-lpu |
| ssRNA40/LyoVec™ | HIV-1 LTR-derived ssRNA / LyoVec™ | TLR2 - / TLR4 - | 0.25 - 5 µg/ml | 4x25µg | tlrl-lrna40 |
| ssRNA41/LyoVec™ | ssRNA40 control / LyoVec™ | TLR2 - / TLR4 - | 0.25 - 5 µg/ml | 4x25µg | tlrl-lrna41 |
| TL8-506 | Benzozepine analog | TLR2 - / TLR4 - | 10 - 100 ng/ml | 500 µg | tlrl-tl8506 |
| TLR8Antagonists | | | | | |
| CU-CPT9a NEW | Potent and selective TLR8 inhibitor | TLR2 - / TLR4 - | 1 - 10 µM | 10 mg | inh-cc9a |
| TLR7/8 Agonists | | | | | |
| CL075 | Thiazoquinoline compound | TLR2 - / TLR4 - | 100 ng - 5 µg/ml | 500 µg 5 mg | tlrl-c75 tlrl-c75-5 |
| CL097 | Imidazoquinoline compound | TLR2 - / TLR4 - | 50 ng - 5 µg/ml | 500 µg 5 mg | tlrl-c97 tlrl-c97-5 |
| Poly(dT) | Thymidine homopolymer ODN (17 mer) | TLR2 - / TLR4 - | 10 µM | 100nmol | tlrl-pt17 |
| R848 (resiquimod) | Imidazoquinoline compound | TLR2 - / TLR4 - | 10 ng - 10 µg/ml | 500 µg 5 mg | tlrl-r848 tlrl-r848-5 |
| R848 VacciGrade™ | Preclinical grade R848 | VacciGrade™ | 10 - 100 µg/mouse | 5 mg | vac-r848 |
| TLR9 Agonists | | | | | |
| E. coli ssDNA/LyoVec™ | E. coli single stranded DNA/LyoVec™ complexes | TLR2 - / TLR4 - | 1 - 10 µg/ml | 200 µg | tlrl-ssec |
| dsDNA-EC | E. coli K12 genomic DNA | TLR2 - / TLR4 - | 30ng-1 µg/ml | 200 µg | tlrl-ecdna |
| ODN 1585 | Stimulatory CpG ODN Type A Mouse specific | TLR2 - / TLR4 - | 1 - 5 µM | 200 µg 1 mg 5 mg | tlrl-1585 tlrl-1585-1 tlrl-1585-5 |
| ODN 1585 control | Negative control for ODN 1585 | TLR2 - / TLR4 - | 1 - 5 µM | 200 µg 1 mg 5 mg | tlrl-1585c tlrl-1585c-1 tlrl-1585c-5 |
| ODN 1585 VacciGrade™ | Preclinical grade ODN 1585 | VacciGrade™ | 20 - 50 µg/mouse | 1 mg | vac-1585-1 |
| ODN 1668 | Stimulatory CpG ODN Type B Mouse specific | TLR2 - / TLR4 - | 1 - 5 µM | 200 µg 1 mg 5 mg | tlrl-1668 tlrl-1668-1 tlrl-1668-5 |
| ODN 1668 control | Negative control for ODN 1668 | TLR2 - / TLR4 - | 1 - 5 µM | 200 µg 1 mg 5 mg | tlrl-1668c tlrl-1668c-1 tlrl-1668c-5 |
| ODN 1668 FITC | FITC-labeled CpG ODN - mouse specific, type B | TLR2 - / TLR4 - | 1 - 5 µM | 50 µg | tlrl-1668f |
| ODN 1826 | Stimulatory CpG ODN Type B Mouse specific | TLR2 - / TLR4 - | 1 - 5 µM | 200 µg 1 mg 5 mg | tlrl-1826 tlrl-1826-1 tlrl-1826-5 |
| ODN 1826 control (ODN 2138) | Negative control for ODN 1826 | TLR2 - / TLR4 - | 1 - 5 µM | 200 µg 1 mg 5 mg | tlrl-1826c tlrl-1826c-1 tlrl-1826c-5 |
| ODN 1826 Biotin | Biotinylated CpG ODN - mouse specific, type B | TLR2 - / TLR4 - | 1 - 5 µM | 2 x 50 µg | tlrl-1826b |
| ODN 1826 FITC | FITC-labeled CpG ODN - mouse specific, type B | TLR2 - / TLR4 - | 1 - 5 µM | 50 µg | tlrl-1826f |
| ODN 1826 VacciGrade™ | Preclinical grade ODN 1826 | VacciGrade™ | 20 - 50 µg/mouse | 1 mg | vac-1826-1 |
| ODN 2006 (ODN7409) | Stimulatory CpG ODN Type B Human specific | TLR2 - / TLR4 - | 1 - 5 µM | 200 µg 1 mg 5 mg | tlrl-2006 tlrl-2006-1 tlrl-2006-5 |
| ODN 2006 control (ODN 2137) | Negative control for ODN 2006 | TLR2 - / TLR4 - | 1 - 5 µM | 200 µg 1 mg 5 mg | tlrl-2006c tlrl-2006c-1 tlrl-2006c-5 |


PRR Ligands


* VacciGrade™ PRR ligands are guaranteed sterile and have minimal endotoxin levels (<0.005 EU/µg).

| PRODUCT | ORIGIN/DESCRIPTION | GRADE* | WORKING CONCENTRATION | QTY | CATALOG CODE |
|-----------------------------|---|-------------|-----------------------|------------------------|---|
| TLR9 Agonists | | | | | |
| ODN 2006 Biotin | Biotinylated CpG ODN - human specific, type B | TLR2-/TLR4- | 1 - 5 µM | 2 x 50 µg | tlrl-2006b |
| ODN 2006 FITC | FITC-labeled CpG ODN - human specific, type B | TLR2-/TLR4- | 1 - 5 µM | 50 µg | tlrl-2006f |
| ODN 2006-G5 | Stimulatory CpG ODN Type B Human specific | TLR2-/TLR4- | 5 µM | 200 µg 1 mg 5 mg | tlrl-2006g5 tlrl-2006g5-1 tlrl-2006g5-5 |
| ODN 2006-G5 Control | Negative control for ODN 2006-G5 | TLR2-/TLR4- | 5 µM | 200 µg | tlrl-2006g5c |
| ODN 2006 VacciGrade™ | Preclinical grade ODN 2006 | VacciGrade™ | 20 - 50 µg/mouse | 1 mg | vac-2006-1 |
| ODN 2007 | Stimulatory CpG ODN Type B Bovine / porcine | TLR2-/TLR4- | 5 µM | 200 µg 1 mg 5 mg | tlrl-2007 tlrl-2007-1 tlrl-2007-5 |
| ODN 2007 control | Negative control for ODN 2007 | TLR2-/TLR4- | 5 µM | 200 µg 1 mg 5 mg | tlrl-2007c tlrl-2007c-1 tlrl-2007c-5 |
| ODN 2216 | Stimulatory CpG ODN Type A Human specific | TLR2-/TLR4- | 1 - 5 µM | 200 µg 1 mg 5 mg | tlrl-2216 tlrl-2216-1 tlrl-2216-5 |
| ODN 2216 control (ODN 2138) | Negative control for ODN 2216 | TLR2-/TLR4- | 1 - 5 µM | 200 µg 1 mg 5 mg | tlrl-2243 tlrl-2243-1 tlrl-2243-5 |
| ODN 2216 Biotin | Biotinylated CpG ODN - human specific, type A | TLR2-/TLR4- | 1 - 5 µM | 2 x 50 µg | tlrl-2216b |
| ODN 2216 FITC | FITC-labeled CpG ODN - human specific, type A | TLR2-/TLR4- | 1 - 5 µM | 50 µg | tlrl-2216f |
| ODN 2336 | Stimulatory CpG ODN Type A Human specific | TLR2-/TLR4- | 1 - 5 µM | 200 µg 1 mg 5 mg | tlrl-2336 tlrl-2336-1 tlrl-2336-5 |
| ODN 2336 control | Negative control for ODN 2336 | TLR2-/TLR4- | 1 - 5 M | 200 µg 1 mg 5 mg | tlrl-2336c tlrl-2336c-1 tlrl-2336c-5 |
| ODN 2395 | Stimulatory CpG ODN Type C Human / mouse | TLR2-/TLR4- | 5 µM | 200 µg 1 mg 5 mg | tlrl-2395 tlrl-2395-1 tlrl-2395-5 |
| ODN 2395 control | Negative control for ODN 2395 | TLR2-/TLR4- | 1 - 5 µM | 200 µg 1 mg 5 mg | tlrl-2395c tlrl-2395c-1 tlrl-2395c-5 |
| ODN 2395 FITC | FITC-labeled CpG ODN - human specific, type C | TLR2-/TLR4- | 1 - 5 µM | 50 µg | tlrl-2395f |
| ODN 2395 VacciGrade™ | Preclinical grade ODN 2395 | VacciGrade™ | 20 - 50 µg/mouse | 1 mg | vac-2395-1 |
| ODN BW006 (ODN684) | Class B CpG ODN, human & mouse | TLR2-/TLR4- | 1 - 50 µg/ml | 200 µg | tlrl-bw006 |
| ODN BW007 | Negative control for ODN BW006 | TLR2-/TLR4- | 1 - 50 µg/ml | 200 µg | tlrl-bw007 |
| ODN D-SL01 | Class B CpG ODN, multispecies | TLR2-/TLR4- | 1 - 5 µM | 200 µg | tlrl-dsl01 |
| ODN D-SL03 | Class C CpG ODN, multispecies | TLR2-/TLR4- | 1 - 5 µM | 200 µg | tlrl-dsl03 |
| ODN M362 | Stimulatory CpG ODN Type C Human / mouse | TLR2-/TLR4- | 1 - 5 µM | 200 µg 1 mg 5 mg | tlrl-m362 tlrl-m362-1 tlrl-m362-5 |
| ODN M362 Control | Negative control for ODN M362 | TLR2-/TLR4- | 5 µM | 200 µg 1 mg 5 mg | tlrl-m362c tlrl-m362c-1 tlrl-m362c-5 |
| TLR9 Antagonists | | | | | |
| ODN 2088 | Inhibitory ODN, mouse preferred | TLR2-/TLR4- | 100 nM - 10 µM | 200 µg 1 mg 5 mg | tlrl-2088 tlrl-2088-1 tlrl-2088-5 |
| ODN 2088 control | Negative control for ODN 2088 | TLR2-/TLR4- | 100 nM - 10 µM | 200 µg 1 mg 5 mg | tlrl-2088c tlrl-2088c-1 tlrl-2088c-5 |
| ODN 4084-F | Class B inhibitory ODN | TLR2-/TLR4- | 100 nM - 10 µM | 200 µg | tlrl-4084 |
| ODN INH-18 | Inhibitory ODN, human & mouse | TLR2-/TLR4- | 0.1 - 10 µM | 200 µg | tlrl-inh18 |




TLR & NLR Signaling Pathways





CLR, RLR & CDS Signaling Pathways



PRR Ligands

*To ensure the **absence** of bacterial contaminants (i.e. lipoproteins and endotoxins), TLR2 and TLR4 activation has been assessed by cellular assays.

| PRODUCT | ORIGIN/DESCRIPTION | GRADE* | WORKING CONCENTRATION | QTY | CATALOG CODE |
|------------------------------------|---|----------------|-----------------------|----------------|--------------------------------|
| TLR9 Antagonists | | | | | |
| ODN TTAGGG (A151) | Inhibitory ODN, human preferred | TLR2 / TLR4 - | 100 nM - 10 µM | 200 µg 1 mg | tlrl-ttag151 tlrl-ttag151-1 |
| ODN TTAGGG (A151) control | Negative control for ODN TTAGGG | TLR2 / TLR4 - | 100 nM - 10 µM | 200 µg 1 mg | tlrl-ttagc tlrl-ttagc-1 |
| TLR13 Agonists | | | | | |
| ORN Sa19 | <i>S. aureus</i> 23S rRNA-derived oligoribonucleotide | TLR2 / TLR4 - | 0.02 - 2 µg/ml | 200 µg | tlrl-orn19 |
| ORN Sa19 Control | Control oligoribonucleotide for ORN Sa19 | TLR2 / TLR4 - | 0.02 - 2 µg/ml | 200 µg | tlrl-orn19c |
| NLR LIGANDS | | | | | |
| NOD1 Agonists | | | | | |
| C12-iE-DAP | Acylated derivative of iE-DAP | TLR2 / TLR4 - | 1 ng - 1 µg/ml | 1 mg | tlrl-c12dap |
| C14-Tri-LAN-Gly | Meso-lanthionine tri-peptide (CL243) | TLR2 / TLR4 - | 1 ng - 1 µg/ml | 1 mg | tlrl-ctlg |
| iE-DAP | D-γ-Glu-mDAP | TLR2 / TLR4 - | 1 - 100 µg/ml | 5 mg | tlrl-dap |
| iE-Lys | iE-DAP negative control | TLR2 / TLR4 - | 1 - 100 µg/ml | 5 mg | tlrl-lys |
| Tri-DAP | L-Ala-γ-D-Glu-mDAP | TLR2 / TLR4 - | 100 ng - 10 µg/ml | 1 mg | tlrl-tdap |
| NOD2 Agonists | | | | | |
| CL429 | Pam2C-conjugated murabutide | TLR2 +/ TLR4 - | 1 ng - 10 µg/ml | 5 mg | tlrl-c429 |
| CL429 VacciGrade™ | TLR2/NOD2 agonist | VacciGrade™ | 20-50 µg/mouse | 5 mg | vac-c429 |
| L18-MDP | Muramyl dipeptide with a C18 fatty acid chain | TLR2 / TLR4 - | 1 - 100 ng/ml | 1 mg | tlrl-lmdp |
| MDP | Muramyl dipeptide (L-D isoform, active) | TLR2 / TLR4 - | 10 ng - 10 µg/ml | 5 mg | tlrl-mdp |
| MDP control | Muramyl dipeptide (D-D isoform, inactive) | TLR2 / TLR4 - | 10 ng - 10 µg/ml | 5 mg | tlrl-mdpc |
| M-Tri _{Lys} | Synthetic muramyl tripeptide | TLR2 / TLR4 - | 100 ng - 10 µg/ml | 1 mg | tlrl-mtl |
| Murabutide | Synthetic derivative of muramyl dipeptide | TLR2 / TLR4 - | 1 - 100 ng/ml | 5 mg | tlrl-mbt |
| N-Glycolyl-MDP | N-glycolylated muramyl dipeptide | TLR2 / TLR4 - | 100 ng - 10 µg/ml | 5 mg | tlrl-gmdp |
| NOD1/2 Agonists | | | | | |
| M-Tri _{DAP} | MurNAc-L-Ala-γ-D-Glu-mDAP | TLR2 / TLR4 - | 100 ng - 10 µg/ml | 1 mg | tlrl-mtd |
| PGN-ECndi Ultrapure | Insoluble peptidoglycan from <i>E. coli</i> K12 | TLR2 / TLR4 - | 1 - 5 µg/ml | 5 mg | tlrl-kipgn |
| PGN-ECndss Ultrapure | Soluble sonicated peptidoglycan from <i>E. coli</i> K12 | TLR2 / TLR4 - | 1 - 5 µg/ml | 1 mg | tlrl-ksspgn |
| PGN-SAndi Ultrapure | Insoluble peptidoglycan from <i>S. aureus</i> | TLR2 / TLR4 - | 1 - 5 µg/ml | 5 mg | tlrl-sipgn |
| INFLAMMASOME INDUCERS | | | | | |
| AIM2 Inflammasome Agonists | | | | | |
| Poly(dA:dT) Naked | Poly(dA-dT)•poly(dT-dA) | TLR2 / TLR4 - | 10 ng/ml - 1 µg/ml | 200 µg 1 mg | tlrl-patn tlrl-patn-1 |
| Poly(dA:dT)/LyoVec | Poly(dA-dT)•poly(dT-dA)/LyoVec™ complexes | TLR2 / TLR4 - | 10 ng - 10 µg/ml | 100 µg | tlrl-patc |
| Poly(dA:dT)/Rhodamine | Rhodamine labeled poly(dA-dT)•poly(dT-dA) | TLR2 / TLR4 - | 100 ng - 10 µg/ml | 10 µg | tlrl-patrh |
| NLRc4 Inflammasome inducers | | | | | |
| LFn-Needle NEW | T3SS Needle protein fused to Lethal Factor | TLR2/TLR4- | 0.16 - 100 ng/ml | 5 µg | tlrl-nl |
| LFn-Rod NEW | T3SS Inner Rod protein fused to Lethal | TLR2/TLR4 | 16 ng/ml - 10 µg/ml | 50 µg | tlrl-rod |
| NLRP1 Inflammasome Inducers | | | | | |
| L18-MDP | Muramyl dipeptide with a C18 fatty acid chain | TLR2 / TLR4 - | 1 - 100 ng/ml | 1 mg | tlrl-lmdp |
| MDP | Muramyl dipeptide (L-D isoform, active) | TLR2 / TLR4 - | 10 ng - 10 µg/ml | 5 mg | tlrl-mdp |
| NLRP3 Inflammasome Inducers | | | | | |
| Alum | Alum Hydroxide suspension | TLR2 / TLR4 - | 50-500 µg/ml | 500µL | tlrl-aloh |
| ATP | Adenosine 5'-triphosphate disodium salt | TLR2 / TLR4 - | 5 mM | 1 g | tlrl-atpl |

PRR Ligands

* VacciGrade™ PRR ligands are guaranteed sterile and have minimal endotoxin levels (<0.005 EU/µg).

| PRODUCT | ORIGIN/DESCRIPTION | GRADE* | WORKING CONCENTRATION | QTY | CATALOG CODE |
|--|--|-----------------|--------------------------|-----------------------|------------------------------------|
| NLRP3 Inflammasome Inducers | | | | | |
| CPPD Crystals | Calcium pyrophosphate dihydrate | TLR2 - / TLR4 - | 1 - 50 µg/ml | 5 mg | tlrl-cppd |
| Hemozoin | Synthetic heme crystal | TLR2 - / TLR4 - | 50 - 400 µg/ml | 5 mg | tlrl-hz |
| MSU Crystals | Monosodium urate (uric acid) | TLR2 - / TLR4 - | 50 - 200 µg/ml | 5 mg 25 mg | tlrl-msu tlrl-msu-25 |
| Nano-SiO ₂ | Nanoparticles of silica dioxide | TLR2 - / TLR4 - | 10 - 200 µg/ml | 20 mg | tlrl-sio-2 |
| Nigericin | Nigericin, sodium salt | TLR2 - / TLR4 - | 1 µM | 10 mg 50 mg | tlrl-nig tlrl-nig-5 |
| TDB | Synthetic analog of the cord factor | TLR2 - / TLR4 - | 1 - 100 µg/ml | 2 mg | tlrl-tdb |
| Non-canonical Inflammasome Inducers | | | | | |
| E. coli OMVs | Purified outer membrane vesicles from <i>E. coli</i> BL21 | TLR2 + / TLR4 + | 0.2-100 µg/ml | 100 µg | tlrl-omv-1 |
| E. coli OMVs InvivoFit™ | Sterile grade of outer membrane vesicles from <i>E. coli</i> | TLR2 + / TLR4 + | 10-100 µg/mouse | 500 µg | tlrl-omv |
| Curdlan | Beta-1,3-glucan from <i>Alcaligenes faecalis</i> | TLR2 - / TLR4 - | 0.1 - 100 µg/ml | 1 g | tlrl-curd |
| HKCA | Heat-killed <i>Candida albicans</i> | TLR2 - / TLR4 - | 10 ⁸ cells/ml | 10 ⁹ cells | tlrl-hkca |
| Pustulan | Beta-glucan from <i>Lasallia pustulata</i> | TLR2 - / TLR4 - | 0.1 - 100 µg/ml | 100 mg | tlrl-pst |
| Zymosan Depleted | Hot alkali treated zymosan | TLR2 - / TLR4 - | 100 µg/ml | 10 mg | tlrl-zyd |
| RLR LIGANDS | | | | | |
| RIG-I Agonists | | | | | |
| 3p-hpRNA | 5' triphosphate hairpin RNA | TLR2 - / TLR4 - | 10 ng - 1 µg/ml | 25 µg | tlrl-hprna |
| 3p-hpRNA/LyoVec NEW | 3p-hpRNA/LyoVec complexes | TLR2 - / TLR4 - | 10 ng - 3 µg/ml | 25 µg | tlrl-hprnalu |
| 5'ppp-dsRNA | 5'Triphosphate blunt-end double-stranded RNA | TLR2 - / TLR4 - | 300 ng - 1 µg/ml | 25 µg 100 µg | tlrl-3prna tlrl-3prna-100 |
| 5'ppp-dsRNA/LyoVec™ | 5'ppp-dsRNA/LyoVec™ complexes | TLR2 - / TLR4 - | 300 ng - 1 µg/ml | 25 µg 100 µg | tlrl-3prnalu tlrl-3prnalu-100 |
| 5'ppp-dsRNA Control | Blunt-end double-stranded RNA, control | TLR2 - / TLR4 - | 300 ng - 1 µg/ml | 25 µg 100 µg | tlrl-3prnac tlrl-3prnac-100 |
| 5'ppp-dsRNA Control/LyoVec™ | 5'ppp-dsRNA Control/LyoVec™ complexes | TLR2 - / TLR4 - | 300 ng - 1 µg/ml | 25 µg 100 µg | tlrl-3prnaclu tlrl-3prnaclu-100 |
| RIG-I/MDA-5 Agonists | | | | | |
| Poly(I:C) (HMW)/LyoVec™ | Poly(I:C) (HMW)/LyoVec™ complexes | TLR2 - / TLR4 - | 100 ng - 1 µg/ml | 100 µg | tlrl-piclv |
| Poly(I:C) (LMW)/LyoVec™ | Poly(I:C) (LMW)/LyoVec™ complexes | TLR2 - / TLR4 - | 100 ng - 1 µg/ml | 100 µg | tlrl-piclwlv |
| CLR LIGANDS | | | | | |
| Dectin-1 Agonists | | | | | |
| Beta-Glucan Peptide | Beta-glucan from <i>Trametes versicolor</i> | TLR2 - / TLR4 - | 1 - 100 µg/ml | 50 mg | tlrl-bgp |
| Curdlan | Beta-1,3-glucan from <i>Alcaligenes faecalis</i> | TLR2 - / TLR4 - | 100 µg/ml | 1 g | tlrl-curd |
| HKCA | Heat-killed <i>Candida albicans</i> | TLR2 - / TLR4 - | 10 ⁸ cells/ml | 10 ⁹ cells | tlrl-hkca |
| Laminarin | Soluble beta-glucan from <i>Laminaria digitata</i> | TLR2 + / TLR4 - | 1 - 100 µg/ml | 100 mg | tlrl-lam |
| Pustulan | Beta-glucan from <i>Lasallia pustulata</i> | TLR2 - / TLR4 - | 1 - 100 µg/ml | 100 mg | tlrl-pst |
| Scleroglucan | Beta-glucan from <i>Sclerotium rolfsii</i> | TLR2 + / TLR4 + | 1 - 100 µg/ml | 100 mg | tlrl-scg |
| WGP Dispersible | Whole Glucan Particles, insoluble | TLR2 - / TLR4 - | 1 - 200 µg/ml | 50 mg | tlrl-wgp |
| WGP Soluble | Whole Glucan Particles, soluble | TLR2 - / TLR4 - | 1 ng - 1 µg/ml | 50 mg | tlrl-wgps |
| Zymosan | Cell wall preparation from <i>S. cerevisiae</i> | TLR2 + / TLR4 - | 1 - 10 µg/ml | 100 mg | tlrl-zyn |
| Zymosan Depleted | Hot alkali treated zymosan | TLR2 - / TLR4 - | 100 µg/ml | 10 mg | tlrl-zyd |
| Dectin-2 Agonist | | | | | |
| Furfurman | Malassezia furfur cell wall preparation | TLR2 - / TLR4 - | 100 ng - 10 µg/ml | 10 mg | tlrl-ffm |

PRR Ligands

*To ensure the **absence** of bacterial contaminants (i.e. lipoproteins and endotoxins), TLR2 and TLR4 activation has been assessed by cellular assays.

| PRODUCT | ORIGIN/DESCRIPTION | GRADE* | WORKING CONCENTRATION | QTY | CATALOG CODE |
|------------------------------------|---|----------------|-----------------------|----------------|----------------------------|
| Mincle Agonists | | | | | |
| β-GlcCer | Synthetic β-glucosylceramide | TLR2-/TLR4- | 1-10 µg/ml | 5 mg | tlrl-bglcer |
| GlcC ₁₄ C ₁₈ | Glucosyl-6-tetradecyloctadecanoate | TLR2 -/ TLR4 - | 10 ng - 1 µg/ml | 2 mg | tlrl-gcc |
| HKMT | Heat Killed <i>Mycobacterium tuberculosis</i> | TLR2 +/ TLR4 - | 10 - 100 µg/ml | 10 mg 50 mg | tlrl-hkmt-1 tlrl-hkmt-5 |
| TDB | Synthetic analog of the cord factor | TLR2 -/ TLR4 - | 1 - 100 µg/ml | 2 mg | tlrl-tdb |
| TDB VacciGrade™ | Preclinical grade TDB | VacciGrade™ | 1 - 100 µg/mouse | 2 mg | vac-tdb |
| TDB-HS15 | Formulated TDB | TLR2 -/ TLR4 - | 0.3 - 100 µg/ml | 2 mg | tlrl-stdb |
| TDM | Trehalose-6,6-dimycolate; also known as cord factor | TLR2 -/ TLR4 - | 300 ng-10 µg/ml | 2 mg | tlrl-tdm |

CDS & STING LIGANDS

| | | | | | |
|-----------------------|---|----------------|-------------------|----------------|--------------------------------|
| CDS Agonists | | | | | |
| ODN TTAGGG (A151) | Inhibitory ODN, human preferred | TLR2 -/ TLR4 - | 100 nM - 10 µM | 200 µg 1 mg | tlrl-ttag151 tlrl-ttag151-1 |
| dsDNA-EC | <i>E. coli</i> K12 genomic DNA | TLR2 -/ TLR4 - | 30 ng - 1 µg/ml | 200 µg | tlrl-ecdna |
| G3-YSD | Y-form DNA | TLR2 -/ TLR4 - | 100 ng - 1 µg/ml | 200 µg | tlrl-ydna |
| G3-YSD Control | Control for Y-form DNA | TLR2 -/ TLR4 - | 100 ng - 1 µg/ml | 200 µg | tlrl-ydnac |
| HSV-60 Naked | HSV1-derived 60 bp oligonucleotide | TLR2 -/ TLR4 - | 30 ng - 10 µg/ml | 200 µg | tlrl-hsv60n |
| HSV-60 LyoVec™ | Precomplexed HSV1-derived 60 bp ODN | TLR2 -/ TLR4 - | 300 ng - 10 µg/ml | 100 µg | tlrl-hsv60c |
| HSV-60c Naked | Control for HSV-60 ODN | TLR2 -/ TLR4 - | 30 ng - 10 µg/ml | 200 µg | tlrl-hsv60cn |
| HSV-60c/LyoVec™ | Precomplexed control for HSV-60 ODN | TLR2 -/ TLR4 - | 300 ng - 10 µg/ml | 100 µg | tlrl-hsv60cc |
| ISD Naked | Interferon stimulatory DNA | TLR2 -/ TLR4 - | 100 ng - 10 µg/ml | 200 µg | tlrl-isdn |
| ISD/LyoVec™ | Precomplexed interferon stimulatory DNA | TLR2 -/ TLR4 - | 300 ng - 10 µg/ml | 100 µg | tlrl-isdc |
| ISD Control Naked | Non-immunostimulatory ODN | TLR2 -/ TLR4 - | 100 ng - 10 µg/ml | 200 µg | tlrl-isdcn |
| ISD Control/LyoVec™ | Precomplexed non-immunostimulatory ODN | TLR2 -/ TLR4 - | 300 ng - 10 µg/ml | 100 µg | tlrl-isdcc |
| Poly(dA:dT) Naked | Poly(dA-dT)•poly(dT-dA) | TLR2 -/ TLR4 - | 1 - 5 µg/ml | 200 µg 1 mg | tlrl-patn tlrl-patn-1 |
| Poly(dA:dT)/LyoVec™ | Poly(dA-dT)•poly(dT-dA)/LyoVec™ complexes | TLR2 -/ TLR4 - | 1 - 5 µg/ml | 100 µg | tlrl-patc |
| Poly(dA:dT)/Rhodamine | Rhodamine labeled poly(dA-dT)•poly(dT-dA) | TLR2 -/ TLR4 - | 30 ng - 10 µg/ml | 10 µg | tlrl-patrh |
| Poly(dG:dC) Naked | Poly(dG-dC)•poly(dG-dC) | TLR2 -/ TLR4 - | 10 ng - 10 µg/ml | 200 µg | tlrl-pgcn |
| Poly(dG:dC)/LyoVec™ | Poly(dG-dC)•poly(dG-dC)/LyoVec™ complexes | TLR2 -/ TLR4 - | 10 ng - 10 µg/ml | 100 µg | tlrl-pgcc |
| VACV-70 Naked | Vaccinia virus-derived 70 bp oligonucleotide | TLR2 -/ TLR4 - | 30 ng - 10 µg/ml | 200 µg | tlrl-vav70n |
| VACV-70/LyoVec™ | Precomplexed vaccinia virus-derived 70 bp ODN | TLR2 -/ TLR4 - | 300 ng - 10 µg/ml | 100 µg | tlrl-vav70c |
| VACV-70c Naked | Control for VACV-70 ODN | TLR2 -/ TLR4 - | 30 ng - 10 µg/ml | 200 µg | tlrl-vav70cn |
| VACV-70c/LyoVec™ | Precomplexed control for VACV-70 ODN | TLR2 -/ TLR4 - | 300 ng - 10 µg/ml | 100 µg | tlrl-vav70cc |

STING Agonists

| | | | | | |
|---------------------------|--|----------------|--------------------|----------------------------------|---|
| 2'2'-cGAMP | 2'5'-2'5' Cyclic GMP-AMP | TLR2 -/ TLR4 - | 100 ng - 100 µg/ml | 500 µg 1 mg | tlrl-nacga22 tlrl-nacga22-1 |
| 2'3'-cGAMP | 2'5'-3'5' Cyclic GMP-AMP | TLR2 -/ TLR4 - | 100 ng - 100 µg/ml | 200 µg 500 µg 1 mg 5 mg | tlrl-nacga23-02 tlrl-nacga23 tlrl-nacga23-1 tlrl-nacga23-5 |
| 2'3'-cGAMP Control | Linear dinucleotide analog of 2'3'-cGAMP | TLR2 -/ TLR4 - | 100 ng - 100 µg/ml | 1 mg | tlrl-nagpap |
| 2'3'-cGAMP VacciGrade™ | Preclinical grade 2'5'-3'5' cyclic GMP-AMP | VacciGrade™ | 5 - 50 µg/mouse | 1 mg | vac-nacga23 |
| 2'3'-cGAM(PS)2 (Rp/Sp) | Bis-phosphorothioate analog of 2'3'-cGAMP | TLR2 -/ TLR4 - | 100 ng - 100 µg/ml | 250 µg | tlrl-nacga2srs |
| 2'3'-c-di-AMP | Synthetic analog of c-di-AMP | TLR2 -/ TLR4 - | 1 - 100 µg/ml | 500 µg | tlrl-nacda23 |
| 2'3'-c-di-AM(PS)2 (Rp,Rp) | Bisphosphorothioate analog of 2'3'-c-di-AMP | TLR2 -/ TLR4 - | 0.1-10 µg/ml | 100 µg 500 µg | tlrl-nada2r-01 tlrl-nacda2r |
| 2'3'-c-di-AM(PS)2 (Rp,Rp) | Preclinical grade of bisphosphorothioate analog of 2'3'-c-di-AMP | VacciGrade™ | 5-50 µg/mouse | 500 µg | vac-nacda2r |

PRR Ligands

* VacciGrade™ PRR ligands are guaranteed sterile and have minimal endotoxin levels (<0.005 EU/µg).

| PRODUCT | ORIGIN/DESCRIPTION | GRADE* | WORKING CONCENTRATION | QTY | CATALOG CODE | |
|-----------------------------------|--|--|-----------------------|---------------------------|--|------------------------|
| STING Agonists | | | | | | |
| 2'3'-c-di-GMP | Synthetic analog of c-di-GMP | TLR2 -/ TLR4 - | 1 - 100 µg/ml | 500 µg | tlrl-nacdg23 | |
| 3'3'-cGAMP | 3'5'-3'5' Cyclic GMP-AMP | TLR2 -/ TLR4 - | 100 ng - 100 µg/ml | 500 µg 1 mg 5x0.5mg | tlrl-nacga tlrl-nacga-1 tlrl-nacga-2.5 | |
| 3'3'-cGAMP Control | Linear dinucleotide analog of 3'3'-cGAMP | TLR2 -/ TLR4 - | 100 ng - 100 µg/ml | 1 mg | tlrl-nagpap | |
| 3'3'-cGAMP Fluorinated | Difluor cyclic [G(3',5')pA(3',5')p] | TLR2 -/ TLR4 - | 100 ng - 10 µg/ml | 100 µg | tlrl-nacgaf | |
| cAIMP (CL592) | Cyclic [A(3',5')pI(3',5')p] | TLR2 -/ TLR4 - | 300 ng - 30 µg/ml | 500 µg | tlrl-nacai | |
| cAIMP Difluor (CL614) | Difluor cyclic [A(3',5')pI(3',5')p] | TLR2 -/ TLR4 - | 100 ng - 30 µg/ml | 250 µg | tlrl-nacaidf | |
| cAIM(PS)2 Difluor (Rp/Sp) | Difluor and bisphosphorothioate analog of cAIMP | TLR2 -/ TLR4 - | 100 ng - 30 µg/ml | 100 µg | tlrl-nacairs | |
| c-di-AMP | 3'5' Cyclic di-AMP | TLR2 -/ TLR4 - | 1 - 100 µg/ml | 1 mg 5 x 1 mg | tlrl-nacda tlrl-nacda-5 | |
| c-di-AMP Control | Linear dinucleotide analog of c-di-AMP - pApA | TLR2 -/ TLR4 - | 1 - 100 µg/ml | 1 mg | tlrl-napapa | |
| c-di-AMP VacciGrade™ | Sterile 3'5' cyclic di-AMP | VacciGrade™ | 5 - 50 µg/mouse | 1 mg | vac-nacda | |
| c-di-AMP Fluorinated | Difluoro [A(3',5')pA(3',5')p] | TLR2 -/ TLR4 - | 300 ng - 30 µg/ml | 100 µg | tlrl-nacdaf | |
| c-di-GMP | 3'5' Cyclic di-GMP | TLR2 -/ TLR4 - | 10 - 100 µg/ml | 1 mg 5 x 1 mg | tlrl-nacdg tlrl-nacdg-5 | |
| c-di-GMP Control | Linear dinucleotide 5'-pGpG; negative control for c-di-GMP | TLR2 -/ TLR4 - | 10 - 100 µg/ml | 1 mg | tlrl-napgpg | |
| c-di-GMP VacciGrade™ | Preclinical grade of cyclic [G(3',5')pG(3',5')p] | VacciGrade™ | 5 - 50 µg/mouse | 1 mg | tlrl-nacdg | |
| c-di-GMP Fluorinated | Difluoro cyclic [G(3',5')pG(3',5')p] | TLR2 -/ TLR4 - | 3 - 100 µg/ml | 100 µg | tlrl-nacdf | |
| c-di-IMP | Cyclic [I(3',5')pI(3',5')p] | TLR2 -/ TLR4 - | 10 - 100 µg/ml | 1 mg | tlrl-nacdi | |
| c-di-UMP | Negative control for c-di-IMP | TLR2 -/ TLR4 - | 1 - 100 µg/ml | 1 mg | tlrl-nacdu | |
| DMXAA | 5,6-dimethyl-xanthenone-4-acetic acid | TLR2 -/ TLR4 - | 10 - 100 µg/ml | 5 mg | tlrl-dmx | |
| CDS & STING Inhibitors | | | | | | |
| G140 | NEW | Human cGAS inhibitor | TLR2-/TLR4- | 1 - 20 µM | 2 mg | inh-g140 |
| RU.521 | NEW | Murine cGAS inhibitor | TLR2-/TLR4- | 200ng/ml - 20µg/ml | 2 mg | inh-ru521 |
| H-151 | NEW | Synthetic Indole Derivative - STING Inhibitor | TLR2-/TLR4- | 4 ng/ml - 4 µg/ml | 10 mg | inh-h151 |
| AhR Ligands | | | | | | |
| AhR Agonists | | | | | | |
| Indirubin | NEW | 2-(2-oxo-1H-indol-3-ylidene)-1H-indol-3-one | TLR2-/TLR4- | 25 - 100 µM | 10 mg | tlrl-indb |
| FICZ | | 6-Formylindolo[3,2-b]carbazole | TLR2 -/ TLR4 - | 50 ng - 5 µg/ml | 1 mg | tlrl-ficz |
| ITE | | 1' H-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester | TLR2 -/ TLR4 - | 1 - 30 µM | 10 mg | tlrl-ite |
| L-Kynurenone | | Beta-Anthraniloyl-L-Alanine | TLR2 -/ TLR4 - | 10 - 100 µg/ml | 10 mg 5x10mg | tlrl-kyn tlrl-kyn-5 |
| AhR Antagonists | | | | | | |
| CH-223191 | | 2-methyl-2H-pyrazole-3-carboxylic acid | TLR2 -/ TLR4 - | 1 - 30 µM | 10 mg | inh-ch22 |

PRR Reporter Cells


Non-Immune Reporter Cells

Cells that constitutively overexpress a given functional PRR gene are valuable tools for many applications, such as the study of the mechanisms involved in PRR recognition or signaling, and the development of novel therapeutic targets. InvivoGen provides human embryonic kidney (HEK)-293 cells that stably express a PRR gene as well as an NF- κ B-inducible SEAP (secreted embryonic alkaline phosphatase) reporter gene to specifically monitor the activation and downstream signaling of a number of PRRs.

HEK293-derived reporter cells

| PRODUCT | CAT. CODE (human) | CAT. CODE (mouse) |
|---------------------------|-------------------|-------------------|
| HEK-Blue™ TLR2 Cells | hkb-htlr2 | hkb-mtlr2 |
| HEK-Blue™ TLR2-TLR1 Cells | hkb-htlr21 | - |
| HEK-Blue™ TLR2-TLR6 Cells | hkb-htlr26 | - |
| HEK-Blue™ TLR3 Cells | hkb-htlr3 | hkb-mtlr3 |
| HEK-Blue™ TLR4 Cells | hkb-htlr4 | hkb-mtlr4 |
| HEK-Blue™ TLR5 Cells | hkb-htlr5 | hkb-mtlr5 |
| HEK-Blue™ TLR7 Cells | hkb-htlr7 | hkb-mtlr7 |
| HEK-Blue™ TLR8 Cells | hkb-htlr8 | hkb-mtlr8 |
| HEK-Blue™ TLR9 Cells | hkb-htlr9 | hkb-mtlr9 |
| HEK-Blue™ TLR13 Cells | - | hkb-mtlr13 |
| HEK-Blue™ NOD1 cells | hkb-hnod1 | hkb-mnod1 |
| HEK-Blue™ NOD2 cells | hkb-hnod2 | hkb-mnod2 |
| HEK-Blue™ Dectin1b cells | hkb-hdect1b | hkb-mdect1b |

For the complete list of non-immune PRR reporter cells please visit www.invivogen.com/hek-293



Immune Reporter Cells

Cells of the immune system, including lymphocytes, monocytes, and macrophages, naturally express a large repertoire of PRRs. InvivoGen has developed stable reporter cells in several well-established immune cell models. These immune reporter cells stably express the Lucia luciferase (encoding a secreted luciferase) and/or SEAP reporter genes under the control of specific inducible promoters allowing to efficiently and conveniently monitor the activity of PRR ligands.

Variety of immune cells

- Human Jurkat T lymphocytes
- Human Ramos B lymphocytes
- Mouse RAW 264.7 macrophages
- Human THP-1 monocytes

InvivoGen's immune reporter cells can be used to study their physiological response to PRR ligands. In addition, some immune reporter cells have been modified (either by overexpression or knock-out of co-receptors) to provide enhanced or diminished responses to specific ligands.

Single or dual pathway studies

- NF- κ B(/AP-1) and/or IRF

Choice of two secreted reporter genes

- SEAP and/or Lucia luciferase

Levels of SEAP and Lucia luciferase can be determined from the same cell supernatant using the highly-sensitive detection reagents QUANTI-Blue™ and QUANTI-Luc™, respectively.

PRR reporter cells are provided with the appropriate selective antibiotic(s) and are guaranteed mycoplasma-free.

| PRODUCT | CAT. CODE |
|--|-------------|
| Jurkat-Dual™ (NF- κ B-Lucia, IRF-SEAP) | jktd-isnf |
| Ramos-Blue™ (NF- κ B-SEAP) | rms-sp |
| Ramos-Blue™ KD-MyD (NF- κ B-SEAP) | rms-kdmyd |
| RAW-Blue™ (NF- κ B-SEAP) | raw-sp |
| RAW-Blue™ ISG (IRF-SEAP) | raw-isg |
| RAW-Lucia™ ISG (IRF-Lucia) | rawl-isg |
| RAW-Lucia™ ISG-KO-cGAS (IRF-Lucia) | rawl-kocgas |
| RAW-Lucia™ ISG-KO-IFI16 (IRF-Lucia) | rawl-koi16 |
| RAW-Lucia™ ISG-KO-IRF3 (IRF-Lucia) | rawl-koirf3 |
| RAW-Lucia™ ISG-KO-STING (IRF-Lucia) | rawl-kostg |
| THP1-Blue™ ISG (IRF-SEAP) | thp-isg |
| THP1-Blue™ NF- κ B (NF- κ B-SEAP) | thp-nfk |
| THP1-Lucia™ ISG (IRF-Lucia) | thpl-isg |
| THP1-Dual™ (NF- κ B-SEAP, IRF-Lucia) | thpd-nfis |
| THP1-Dual™ KO-MyD (NF- κ B-SEAP, IRF-Lucia) | thpd-komyd |

For the complete list of immune PRR reporter cells visit:
www.invivogen.com/reporter-cells